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S U M M A R Y
The Hajj and Umrah religious mass gatherings hosted by the Kingdom of Saudi Arabia can facilitate the
transmission of infectious diseases. The pilgrimages have been associated with a number of local and
international outbreaks of meningococcal disease. These include serogroup A disease outbreaks in
1987 and throughout the 1990s and two international serogroup W135 outbreaks in 2000 and 2001. The
implementation of strict preventative measures including mandatory quadrivalent meningococcal
vaccination and antibiotic chemoprophylaxis for pilgrims from the African meningitis belt has prevented
pilgrimage-associated meningococcal outbreaks since 2001. However, the ﬂuid epidemiology of the
disease and the possibility of outbreaks caused by serogroups not covered by the vaccine or emerging
hyper-virulent strains, mean that the disease remains a serious public health threat during these events.
Continuous surveillance of carriage state and the epidemiology of the disease in the Kingdom and
globally and the introduction of preventative measures that provide broad and long-lasting immunity
and impact carriage are warranted.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Neisseria meningitidis is a Gram-negative, oxidase-positive,
aerobic diplococcus of the family Neisseriaceae. It is an exclusive
human pathogen, carried asymptomatically in the nasopharynx by
about 10% of the general population in non-epidemic periods.1 The
bacterium can be either structurally encapsulated or not encapsu-
lated. Capsule polysaccharide expression plays a key role in
meningococcal pathogenesis and is the basis for the major
serogrouping. In total, 13 serogroups of N. meningitidis have been
reported, but only six serogroups (A, B, C, W135, X, and Y) cause
almost all invasive meningococcal disease worldwide.2,3 N.
meningitidis strains that cause invasive disease are almost always
encapsulated, which helps the survival of the bacteria during
invasive disease and promotes transmission, as well as protection
from antibodies and phagocytic cells.3
Meningococci are spread from person to person through direct
contact with oropharyngeal secretions, and asymptomatic carriers
are the primary source of N. meningitidis transmissions.1 However,
less than 1% of individuals who acquire carriage go on to develop* Corresponding author. Tel.: +96611401555 ext. 1863.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).meningococcal disease.4 The balance between carriage of the
organism and the development of the disease after acquisition is
affected by N. meningitidis characteristics such as bacterial
virulence factors and host and environmental factors including
age, functional or anatomic asplenia, and host immune defense
mechanisms.4,5
Human infections with N. meningitidis remain a serious health
problem; 500 000 to 1.2 million people are infected and between
50 000 and 135 000 die per year worldwide.6 Infections present as a
spectrum of clinical illness, with meningitis (in 80–85% of cases) and
septicemia being the most common. Less common presentations
include pneumonia, septic arthritis, pericarditis, conjunctivitis, and
urethritis.4,7 Even with appropriate treatment, the case fatality rate
is high: 10–40% depending on manifestation, age, and serogroup.3,8
Among survivors, up to 20% suffer from complications and sequelae
of meningococcal infection, including cognitive deﬁcits, bilateral
hearing loss, motor deﬁcits, seizures, visual impairment, hydro-
cephalus, and loss of limbs due to tissue necrosis.4
2. The global epidemiology of meningococcal disease
A notable feature of the meningococcus is its ﬂuid epidemiology.
There are substantial cyclical ﬂuctuations in meningococcal diseaseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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wide. Disease patterns and incidence vary in populations geograph-
ically and over time, among the different invasive meningococcal
serogroups and sequence type clonal complexes.2 The majority of
countries in the high-incidence group are found in the African
meningitis belt, while many moderate-incidence countries are
found in the European and African regions and Australia; low-
incidence countries include many from Europe and the Americas.9
By far the highest incidence of meningococcal disease occurs in
the meningitis belt of Sub-Saharan Africa, extending from Senegal
in the west to Ethiopia in the east. During epidemics, the incidence
can reach 1000 cases per 100 000, or 1% of the population.2
Serogroup A has been the most important serogroup in this
region.2,3 However, serogroup W135 has also been an important
cause of more recent outbreaks. Serogroup C is responsible for
smaller more historical outbreaks and there is recent evidence that
serogroup X may now be emerging in the region.9–11 The
introduction of the newly developed meningococcal A conjugate
vaccine in countries of the African meningitis belt since 2010 is
thought to be responsible for a reduced case load and epidemic
activity in the region in recent years, with expected elimination of
epidemics caused by serogroup A.12,13 However, recent outbreaks
of the disease in the region, including the outbreak in Niger in
2015, the largest meningitis outbreak caused by serogroup C in the
African meningitis belt, show that the disease remains a serious
public health threat in the region.13 In the Americas, the reported
incidence of meningococcal disease is in the range of 0.3–4 cases
per 100 000 population, with some countries such as the USA
currently having incidence at a historical low.2 Most of the disease
in the Americas is caused by serogroups C and B, although
serogroup Y causes a substantial proportion of infections in some
countries and W135 is emerging.9
In European countries, the incidence of the disease ranges from
0.2 to 14 cases per 100 000, mainly caused by serogroup B strains,
particularly in countries that have introduced serogroup C
meningococcal conjugate vaccines.2,9 The incidence of meningo-
coccal disease decreased by one half from 1999 to 2006 in Europe
(following the introduction of serogroup C conjugate vaccines), but
has subsequently stabilized.3 The burden of meningococcal disease
in Asia is much less well deﬁned, but based on limited data, most
disease in Asia is caused by serogroup A and C strains.9 Serogroup B
predominates in Australia and New Zealand, with incidence rates
ranging between 1.4 and 7.9 cases per 100 000 and between
2.6 and 17.4 cases per 100 000, respectively, spanning the pre- and
post-vaccination eras in the two regions.2,9
Limited data are available on the epidemiology of meningococ-
cal disease in the Middle East and North Africa.10 Epidemiology in
this region is affected by its proximity to the African meningitis
belt and by the Hajj and Umrah mass gatherings as key factors
inﬂuencing outbreaks and transmission. Whilst serogroup A
remains the main cause of meningococcal disease in the region,
cases of serogroup B, W135, and Y infections have increasingly
been reported over the last two decades in some countries.9,10 In
the Gulf Cooperation Council States, the limited available data
show reported incidence rates of below 2 cases per 100 000 in
Bahrain, Oman, UAE, Kuwait, and Qatar, with the exception of a few
higher rates in the 1980s.10,14 In Kuwait there were 157 cases of the
disease between 1997 and 2009, most of which were caused by
serogroups B and W135 (43.0% and 22.1%, respectively), but also
serogroups A, C, X, Y, and Z.10,14 A total of 47 cases of
meningococcal disease were reported in Qatar between
2008 and 2010, mostly caused by serogroup W135 (38%), while
48 cases were reported in the UAE in 2008.14 Between 2001 and
2008, 45 cases of meningococcal disease were reported in Oman, a
quarter of which were caused by serogroup W135. Serogroups A, B,
C, and Y caused 21%, 2%, 16%, and 9% of the cases, respectively.14,15In Saudi Arabia, the incidence of the disease has ﬂuctuated over
time, affected by the large numbers of Muslim pilgrims from the
African meningitis belt participating in Hajj and Umrah and the
various outbreaks and disease preventative measures introduced
in the Kingdom over the years. In 1987 the incidence rate in Saudi
Arabia was 12.83 cases per 100 000,10 but following that peak it has
remained relatively low. Between 1995 and 1999, the mean annual
incidence was 0.20 cases per 100 000, ranging from 0.25 cases per
100 000 in 1995 to 0.06 cases per 100 000 in 1999. In the two
outbreak years of 2000 and 2001, the annual incidence increased to
1.42 and 1.32 cases per 100 000, respectively. In the post-epidemic
period between 2002 and 2010, the mean annual incidence did not
exceed 0.06 cases per 100 000, ranging from 0.21 cases per
100 000 in 2002 to 0.01 cases per 100 000 in 2010.16 Serogroups A,
B, C, and W135 have been documented as causing disease in Saudi
Arabia, where serogroups A and W135 are the most commonly
reported.9,10,16
3. Meningococcal disease during Hajj and Umrah
Hajj, the annual pilgrimage to Mecca, Kingdom of Saudi Arabia,
is one of the largest and most geographically and ethnically diverse
mass gatherings in the world.17 Every able-bodied adult Muslim
who can afford to do so is required to make Hajj at least once in his
or her lifetime. Hajj is performed in the 12th month of the Islamic
(lunar) calendar over a few days and attracts over two million
Muslims from more than 183 countries to the Kingdom each
year.18Mecca is also the setting for a relatively smaller ritual called
Umrah, performed year-round. It involves different rituals to Hajj
and is performed in a shorter period of time. Improved
international travel has rendered Umrah very congested, especially
in the 3 months preceding the Hajj when the number of pilgrims
rivals that of Hajj.17 Although not an essential part of the Hajj or
Umrah, many pilgrims also travel to Medina, north of Mecca, as
part of their pilgrimage. Extended stays at holy sites, especially
during Hajj, along with physical exhaustion, extreme heat, and
crowded accommodation, facilitates disease transmission during
these mass gatherings, including meningococcal disease.17,18
4. Meningococcal disease before 1990
Before 1990, meningococcal disease cases during Hajj and
Umrah were not uncommon given the demographics of pilgrims
and their interaction during these events. However, given the
global nature of these mass gatherings, they can be the scene of
large outbreaks of the disease with signiﬁcant national and
international repercussions. The ﬁrst reported international
meningococcal disease outbreak following the Hajj was caused
by N. meningitidis serogroup A and occurred in 1987.19 The
epidemic emphasized the potentially high risk of transmission of
N. meningitidis during the event. Pilgrimage-associated outbreaks
of meningococcal disease also occurred in earlier years, but were
less well documented.20
It is believed that N. meningitidis belonging to the III-1 clonal
complex responsible for epidemics in Nepal, China, Europe, and
possibly India in the 1980s, was introduced into Mecca by South
Asian pilgrims attending the Hajj in 1987.19 Hajjis who became
meningococcal carriers during their stay in Mecca further
disseminated this strain to both developed and developing
countries around the world on their return home.19,21 Outbreaks
were ﬁrst noted among South Asian pilgrims (from Pakistan, India,
Nepal, and Bangladesh), who comprised approximately 10% of the
pilgrims that year and had the highest attack rate during the
epidemic.19,21,22 The disease rapidly spread among pilgrims of
other nationalities and the indigenous Saudi population. The attack
rate was lowest among pilgrims from the meningitis belt of
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meningococcal disease before their arrival at Mecca.22
In 1987, 1841 conﬁrmed cases of meningococcal disease were
reported in Saudi Arabia, predominantly in the three cities most
closely associated with pilgrimage (Mecca, Medina, and Jeddah).20
Internationally, soon after the 1987 pilgrimage, group A meningo-
coccal disease was reported from neighboring Gulf countries and
among Hajjis returning to Europe and North America.19 In the UK,
approximately 10 000 pilgrims travelled to Saudi Arabia in
1987. There were 19 reported cases of serogroup A disease among
the pilgrims returning from Mecca, and 15 subsequent cases
among Muslims over the following 19 months.23 All the primary
cases were adults, but the 15 secondary cases were mainly children
who had had some family contact with relatives who had returned
from the Hajj.22,23 In France, Denamur and colleagues observed
four cases of group A meningococcal disease in the city of Amiens
in the 2 months following the 1987 Hajj.24 The cases were two
children, the mother of one of the children, and a 16-year-old
adolescent. All cases were contacts of pilgrims returning from Hajj.
In 1988 there was a smaller meningococcal serogroup A
outbreak of 305 conﬁrmed cases in Saudi Arabia.20 However, in the
same year, about 7500 cases of group A meningococcal disease
occurred in Chad and a similar epidemic occurred in Sudan with
approximately 18 000 cases reported.19,25 These epidemics may
have been due to the introduction of the III-1 clonal complex into
Sub-Saharan Africa in 1987, as it was not found in earlier isolate
surveys from Africa.26 The introduction of this clonal group may
have interrupted the cyclical pattern of group A meningococcal
disease in the region.19 The 1987 outbreak prompted the Saudi
authorities to implement compulsory vaccination policy with
bivalent A/C vaccine for all pilgrims coming to Mecca.22 As a
consequence, and due to other concerted efforts by the Saudi
authorities, a marked decrease in the number of meningococcal-
related illnesses was observed after 1988.27,28
5. Meningococcal disease in the 1990s
During the early 1990s, two outbreaks of meningococcal
disease were associated with the 1992 Umrah and Ramadan
seasons and occurred among residents and Umrah visitors in
Mecca and Jeddah.20,29 The outbreak strain was serogroup A of the
III-1 clonal complex that caused the 1987 and 1988 outbreaks.
During March and April 1992, 102 bacteriologically conﬁrmed
cases and 80 suspected cases of the disease were identiﬁed in
Mecca. Religious visitors comprised 59% of the conﬁrmed cases and
24% of the suspected cases. The overall case fatality rate for
conﬁrmed cases was 14.7%, but reached 26.7% among pilgrims
from Pakistan.20 During the same period, there were 41 bacterio-
logically conﬁrmed cases of the disease in Jeddah, with 32% of
these being religious visitors and a case fatality rate among
conﬁrmed cases of 19.5%.29 Mass vaccination with a bivalent A/C
polysaccharide vaccine was implemented in both Mecca and
Jeddah, which quelled the outbreaks.20,29 Although these out-
breaks were not known to have spread beyond Saudi Arabia,20 they
were linked to a subsequent epidemic that occurred in Zambia,
Central Africa, during a 2-year period from April 1992 to May
1994.22
There were small outbreaks of meningococcal disease in Mecca
and Jeddah with mainly N. meningitidis serogroup A and serogroup
W135 between 1993 and 1996.28 In 1997, during the lunar month
of Ramadan in the Umrah season, an increase in the number of
cases of serogroup A disease was noted by the Saudi health
authorities. A total of 72 cases of meningococcal disease,
predominantly serogroup A, were reported.30 In Mecca, there
were 53 bacteriologically conﬁrmed cases with a case fatality rate
of 30.2%. Over 70% of the cases were religious visitors.28In general, between 1988 and 1997 there were 483 cases of
meningococcal disease in Mecca with a case fatality rate of 16.8%.
Serogroup A caused most of the cases (89.2%), while serogroups
W135, C, and B caused 6.4%, 3.3%, and 1% of the cases,
respectively.28 Of the 483 cases, 55.7% were religious visitors
who had more than double the case fatality rate of Mecca
residents.28 By 1999 there was no evidence of epidemic
meningococcal disease in Saudi Arabia.27
6. Meningococcal disease in the year 2000 and beyond
At the start of the 2000s there was a shift in the epidemic
pattern of meningococcal disease during Hajj, with a predomi-
nance of N. meningitidis serogroup W135. During March 2000, an
increase in the number of cases of meningococcal disease in Saudi
Arabia was reported that coincided with the Hajj pilgrimage. Cases
from Mecca and Medina during Hajj accounted for 49% of all
notiﬁed annual meningococcal invasive disease cases in the
Kingdom that year.16 The outbreak included 253 cases in Saudi
Arabia (more than one-third were serogroup W135 and less than a
quarter were serogroup A) with sustained community transmis-
sion.30
Approximately 1.7 million Muslim pilgrims originating from
around the world (1.3 million from outside Saudi Arabia) attended
the 2000 Hajj. Shortly after the event, by August 2000, more than
400 serogroup W135 disease cases were reported in Hajj pilgrims
and their close contacts in 16 countries (the UK, Belgium, the USA,
France, Morocco, Kuwait, Saudi Arabia, Oman, Indonesia,
Singapore, Denmark, Finland, Sweden, Norway, Germany, and
the Netherlands), making this the largest recorded outbreak of
meningococcal disease caused by serogroup W135.30,31 The
outbreak had a high fatality with a case fatality rate of 26–28%
in Saudi Arabia, 11–21% in Oman, and up to 60% among patients
admitted to a Mecca hospital.10,30
The 2000 Hajj-associated outbreak strain was a W135:2a:P1.5,2
strain of N. meningitidis belonging to the hypervirulent electro-
phoretic type ET-37 complex and to the sequence type ST11. The
origin of the outbreak strain was of interest, as up to then,
serogroup W135 was associated with only 1–8% of cases of
sporadic meningococcal disease worldwide and was considered to
have low potential to cause invasive disease or outbreaks.31,32
Hence, Mayer and colleagues elucidated the origin of the strain
linked to the 2000 outbreak by investigating 26 outbreak-
associated W135 isolates and 50 W135 isolates collected
worldwide between 1970 and 2000.31 They reported that the
2000 W135 outbreak was not caused by the emergence of a new
W135 strain, but rather the expansion of an ET-37 clone. Members
of the clone have been circulating at least since 1970 and were
associated with the Hajj as early as 1996. Strains most closely
related to those causing the 2000 outbreak were isolated from
Algeria, Mali, and Gambia in the 1990s.31
In 2001, an additional Hajj-related outbreak of W135 menin-
gococcal disease occurred. From February 9 to March 22, 2001,
Saudi Arabian health ofﬁcials reported over 109 cases of
meningococcal meningitis including 35 deaths.33 Of these, more
than 50% were due to N. meningitidis serogroup W135.8 The cases
from Mecca and Medina during the 2001 Hajj accounted for 31% of
all notiﬁed annual meningococcal disease cases in the Kingdom
that year.16 The outbreak spread internationally through pilgrims,
with cases identiﬁed among Hajj pilgrims and their close contacts
globally, including countries in the European Union, Africa, and
Asia.5,33
By May 2001, quadrivalent meningococcal vaccination became
a mandatory visa requirement for all pilgrims from any country; no
meningococcal outbreak was reported in Saudi Arabia during the
2002 Hajj. Nevertheless, in the same year there was a major
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African meningitis belt as a result of the spread of the Hajj outbreak
clone from pilgrims to close contacts.10 Due to the strict
implementation of the quadrivalent vaccine to all local and
international pilgrims, as well as antibiotic prophylaxis for
pilgrims from the African meningitis belt, there have been no
major meningococcal disease outbreaks in the Kingdom related to
Hajj or Umrah since 2001. In fact, between the years 2002 and
2011, there were only 184 laboratory-conﬁrmed cases of
meningococcal disease in the Kingdom (Table 1), only 9% of which
were among visa-holding Hajj or Umrah pilgrims.16 During this
period, the mean annual percentage of all cases reported from
Mecca and Medina was 8.1%, compared to 49% during the year
2000 and 31% during the year 2001.16 In the period between
2012 and 2015 there were only 14 cases of laboratory-conﬁrmed
meningococcal disease in the Kingdom, all of which were outside
Mecca and outside the Hajj season. In Mecca, there have been no
reported meningococcal disease cases since 2006 (Table 1).
7. Concluding remarks
Meningococcal disease remains a major public health threat
with a ﬂuid epidemiology and causes signiﬁcant morbidity and
mortality worldwide. Mass gatherings such as Hajj and Umrah are
fertile grounds for the transmission and spread of meningococcal
disease if appropriate preventative measures are not in place. The
epidemiology of meningococcal disease in Saudi Arabia is affected
by the millions of pilgrims visiting the country annually for Hajj
and Umrah, a sizable proportion of whom originate from the
African meningitis belt. These mass gathering events also have the
potential to impact the global epidemiology of the disease byTable 1
Laboratory-conﬁrmed cases of meningococcal disease in the Kingdom of Saudi
Arabia (KSA) and the Mecca region (1987–2015)
Year No. of cases
in KSA
Main
serogroup(s)
in KSA
No. of cases
in Meccaa
Main
serogroup(s)
in Mecca
1987b 1841 NA NA -
1988b 305 NA 176 A
1989 NA - 43 A
1990 NA - 35 A
1991 NA - 7 A
1992b NA - 102 A
1993 NA - 15 A
1994 NA - 16 A
1995 58 A 23 A
1996 37 A, W135 13 W135, A
1997b 108 A, W135 53 A
1998 42 B 23 B
1999 20 A 5 A, W135
2000b 338 W135, A 173 W135, A
2001b 316 W135 117 W135
2002 55 W135 9 W135
2003 44 A, W135 7 A, W135
2004 10 A 2 A
2005 18 W135, A 1 W135
2006 22 W135, B 0 -
2007 13 W135, A 0 -
2008 7 A 0 -
2009 6 W135 0 -
2010 3 ND 0 -
2011 6 A 0 -
2012 4 A, W135 0 -
2013 2 B, W135 0 -
2014 4 Y 0 -
2015 4 W135 0 -
NA; not available, ND; not determined.
a All cases including pilgrims and non-pilgrims.
b Years of the main meningococcal disease outbreaks.introducing new serogroups to other regions of the world via
returning carrier pilgrims and causing international outbreaks.
Meningococcal disease cases during Hajj and Umrah were not
uncommon before the implementation of strict preventative
measures by the Saudi health authorities. International Hajj-
related outbreaks were documented in 1987 caused by serogroup
A and 2000 and 2001 due to serogroup W135. Local Hajj- and
Umrah-related outbreaks also occurred during this period, mainly
due to serogroup A. In recent years no pilgrimage-associated
meningococcal disease outbreaks have occurred. This is mainly
due to the signiﬁcant efforts the Kingdom has invested in the
prevention and control of the disease during Hajj and Umrah,
including strict vaccination and chemoprophylaxis policies.
Currently, all pilgrims, domestic and international, as well as
local residents of the holy cities and workers in contact with
pilgrims are required to be vaccinated with the quadrivalent
meningococcal (ACYW) vaccine. In addition, antibiotic prophylaxis
is administered at ports of entry for visitors coming from countries
of the African meningitis belt, namely Benin, Burkina Faso,
Cameroon, Chad, Central African Republic, Coˆte d’Ivoire, Eritrea,
Ethiopia, Gambia, Guinea, Guinea-Bissau, Mali, Niger, Nigeria,
Senegal, South Sudan, and Sudan.34 The Saudi health authorities
ensure adherence to these measures by examining vaccination
documents at ports of entry to the Kingdom for all pilgrims. Those
unvaccinated are given antibiotic chemoprophylaxis. The Kingdom
has also invested in a sophisticated surveillance system for
meningococcal disease, which is speciﬁcally enhanced during Hajj
for the early detection and rapid response to any cases of the
disease during the pilgrimage.
Notwithstanding the above, the threat of meningococcal
disease outbreaks during Hajj and Umrah is ever-present. This is
due to the constant importation, mixing and transmission of
various serogroups between pilgrims during the events and the
fact that the currently recommended vaccines do not cover all
serogroups that can potentially cause invasive disease. There is
therefore a potential for a sudden change in epidemiology of
meningococcal disease during the pilgrimages and for local and
international outbreaks to occur. For instance, outbreaks due to
serogroups B or X are particularly concerning. Serogroup B N.
meningitidis is regularly isolated from asymptomatic Hajj and
Umrah pilgrims,35–37 and many countries with large Muslim
populations have been experiencing trends of increasing ser-
ogroup B meningococcal disease.38 Similarly, serogroup X N.
meningitidis, for which no vaccine is currently available, has been
isolated from asymptomatic Hajj pilgrims.39,40 This serogroup has
been causing localized outbreaks in a number of African countries
such as Niger, Uganda, Kenya, Togo, Ghana, and Burkina Faso,2,3
some of which participate in Hajj and Umrah.
Reinforcing, strengthening, reﬁning, and updating the menin-
gococcal preventative measures taking into account data on the
epidemiology of the disease and available preventative tools are
needed. Preventative strategies that impact carriage and trans-
mission should be implemented. Although they prevent invasive
disease, polysaccharide vaccines currently used have a short
protective response and do not prevent the carriage or transmis-
sion of N. meningitidis.3,4 Conjugate meningococcal vaccines are
available and quadrivalent ACYW conjugate vaccines have been
licensed since 2005. In addition to preventing invasive disease, the
conjugate vaccines have the added value of reducing transmission
by preventing or clearing carriage.3,8,12 The conjugate quadrivalent
vaccine should be recommended for the prevention of meningo-
coccal disease during Hajj and Umrah, taking into account its
effectiveness, availability, and cost, especially for low-income
countries from which most pilgrims originate.8
If the quadrivalent conjugate vaccine is used and shown to be
effective in reducing carriage, with the same associated herd
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vaccine,41 there may no longer be a need for the costly and
potentially problematic chemoprophylaxis policy for pilgrims.
New serogroup B vaccines are also available and may be used in
times of outbreaks, as has been done in other countries.42
Surveillance and tracking of carrier state and the occurrence of
invasive meningococcal disease among pilgrims and the disease
epidemiology in their countries of origin are important to guide
interventions to prevent disease and predict and prepare for
potential outbreaks. Early detection of meningococcal disease
cases during Hajj or Umrah pilgrimages through an effective and
responsive surveillance system should continue to prevent and
control any outbreaks.
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